Cardiovascular risk in primary hyperparathyroidism

Ikram Karabila; Khawla Rhouzali; Soumiya Berrabeh; Amel Rania El; Yousra Laalaoua; lamiae zarraa; Siham Rouf; Hanane Latrech

doi:10.1530/endoabs.99.EP526

EP526

Prev Next

Section Contents Cite

Endocrine Abstracts (2024) 99 EP526 | DOI: 10.1530/endoabs.99.EP526

ECE2024 Eposter Presentations Calcium and Bone (102 abstracts)

Cardiovascular risk in primary hyperparathyroidism

Ikram Karabila ¹ , Khawla Rhouzali ¹ , Soumiya Berrabeh ¹ , Rania El Amel ¹ , Yousra Laalaoua ¹ , lamiae zarraa ¹ , Siham Rouf ² & Hanane Latrech ²

Views

Author affiliations

¹Endocrinology-Diabetology and Nutrition Department CHU Mohamed VI Oujda, Faculty of Medicine and Pharmacy, Mohammed First University Oujda, Morocco; ²Endocrinology-Diabetology and Nutrition Department CHU Mohamed VI Oujda, Faculty of Medicine and Pharmacy, Mohammed First University Oujda, Morocco, Laboratory of Epidemiology, Clinical Research and Public Health, Faculty of Medicine and Pharmacy, Mohammed First University Oujda, Morocco

Introduction: Primary hyperparathyroidism (PHPT) is characterized by parathyroid hormone (PTH)-dependent hypercalcemia. It is associated with numerous complications, including an increased risk of cardiovascular disease. The aim of our study is to assess the cardiovascular risk of patients with PHPT.

Methods: We conducted a retrospective descriptive study, including 51 patients hospitalized in the department of endocrinology-diabetology and nutrition for the management of PHPT. Clinical and paraclinical data were collected from medical records and analyzed using the SPSS-V21 software. The Framigham Risk Score (FRS) was used to assess the cardiovascular risk of our patients. It estimates the risk of the occurrence of cardiovascular disease in 10 years. Patients are considered at high risk if the FRS is equal to or higher than 20%, at moderate risk if it ranges from 10 to 19%, and at low risk if the FRS is less than 10%.

Results: Our population consisted of 40 women and 11 men, with a mean age of 55.5±13 years. Type 2 diabetes, hypertension, and dyslipidemia were found in 20.8%, 33.3%, and 41.3%, respectively. Only 2.2% were smokers, and there was no history of cardiopathy among our patients. The majority of cases had moderate cardiovascular risk (44.4%), followed by low risk (33.1%) and high risk (24.4%). The mean FRS in our patients was 14.4±8, and it was significantly correlated to calcemia and PTH1-84 levels (P=0.028, P=0.029).

Conclusion: Cardiovascular risk appears to be correlated with calcemia and PTH1-84 levels in PHPT. Consequently, an assessment of the effect of PHPT treatment on the improvement of cardiovascular risk is necessary in order to improve the quality of life and life expectancy.